You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameConivaptan
Accession NumberDB00872  (APRD01302)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionConivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Structure
Thumb
Synonyms
4'-((4,5-dihydro-2-Methylimidazo(4,5-D)(1)benzazepin-6(1H)-yl)carbonyl)-2-biphenylcarboxanilide
Conivaptan
External Identifiers
  • YM 087
  • YM-087
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vaprisol Dextrose In Plastic Containerinjection, solution20 mg/100mLintravenousCumberland Pharmaceuticals Inc.2008-10-08Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
VaprisolNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Conivaptan hydrochloride
Thumb
  • InChI Key: BTYHAFSDANBVMJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 534.182253835
  • Average Mass: 535.035
DBSALT000793
Categories
UNII0NJ98Y462X
CAS number210101-16-9
WeightAverage: 498.5744
Monoisotopic: 498.205576096
Chemical FormulaC32H26N4O2
InChI KeyInChIKey=IKENVDNFQMCRTR-UHFFFAOYSA-N
InChI
InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
IUPAC Name
N-(4-{4-methyl-3,5,9-triazatricyclo[8.4.0.0²,⁶]tetradeca-1(14),2(6),3,10,12-pentaene-9-carbonyl}phenyl)-2-phenylbenzamide
SMILES
CC1=NC2=C(CCN(C(=O)C3=CC=C(NC(=O)C4=CC=CC=C4C4=CC=CC=C4)C=C3)C3=CC=CC=C23)N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-phenylbenzamides. These are benzamides that are N-linked to a phenyl group via the carboxamide group.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzamides
Direct ParentN-phenylbenzamides
Alternative Parents
Substituents
  • N-phenylbenzamide
  • Biphenyl
  • Benzazepine
  • N-arylamide
  • Aminobenzoic acid or derivatives
  • Benzoic acid or derivatives
  • Benzoyl
  • Azepine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
PharmacodynamicsConivaptan is a nonpeptide, dual antagonist of arginine vasopressin (AVP) V1A and V2 receptors. The level of AVP in circulating blood is critical for the regulation of water and electrolyte balance and is usually elevated in both euvolemic and hypervolemic hyponatremia. The AVP effect is mediated through V2 receptors, which are functionally coupled to aquaporin channels in the apical membrane of the collecting ducts of the kidney. These receptors help to maintain plasma osmolality within the normal range by increasing permeability of the renal collecting ducts to water. Vasopressin also causes vasoconstriction through its actions on vascular 1A receptors. The predominant pharmacodynamic effect of conivaptan in the treatment of hyponatremia is through its V2 antagonism of AVP in the renal collecting ducts, an effect that results in aquaresis, or excretion of free water. Conivaptan's antagonist activity on V1A receptors may also cause splanchnic vasodilation, resulting in possible hypotension or variceal bleeding in patients with cirrhosis. The pharmacodynamic effects of conivaptan include increased free water excretion (i.e., effective water clearance [EWC]) generally accompanied by increased net fluid loss, increased urine output, and decreased urine osmolality.
Mechanism of actionConivaptan is a dual AVP antagonist with nanomolar affinity for human arginine vasopressin V1A and V2 receptors in vitro. This antagonism occurs in the renal collecting ducts, resulting in aquaresis, or excretion of free water.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding99%
Metabolism

CYP3A4 is the sole cytochrome P450 isozyme responsible for the metabolism of conivaptan. Four metabolites have been identified. The pharmacological activity of the metabolites at V1a and V2 receptors ranged from approximately 3-50% and 50-100% that of conivaptan, respectively.

Route of eliminationNot Available
Half life5 hours
ClearanceNot Available
ToxicityAlthough no data on overdosage in humans are available, conivaptan has been administered as a 20 mg loading dose on Day 1 followed by continuous infusion of 80 mg/day for 4 days in hyponatremia patients and up to 120 mg/day for 2 days in CHF patients. No new toxicities were identified at these higher doses, but adverse events related to the pharmacologic activity of conivaptan, e.g. hypotension and thirst, occurred more frequently at these higher doses.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9522
Caco-2 permeable+0.5291
P-glycoprotein substrateSubstrate0.5919
P-glycoprotein inhibitor IInhibitor0.6901
P-glycoprotein inhibitor IIInhibitor0.8429
Renal organic cation transporterNon-inhibitor0.6631
CYP450 2C9 substrateNon-substrate0.7671
CYP450 2D6 substrateNon-substrate0.7534
CYP450 3A4 substrateSubstrate0.6602
CYP450 1A2 substrateInhibitor0.7008
CYP450 2C9 inhibitorInhibitor0.5368
CYP450 2D6 inhibitorNon-inhibitor0.6597
CYP450 2C19 inhibitorInhibitor0.8477
CYP450 3A4 inhibitorInhibitor0.9027
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9043
Ames testNon AMES toxic0.6672
CarcinogenicityNon-carcinogens0.8831
BiodegradationNot ready biodegradable0.9584
Rat acute toxicity2.5446 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Inhibitor0.8456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Astellas pharma us inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionintravenous20 mg/100mL
Prices
Unit descriptionCostUnit
Vaprisol 20 mg/100 ml bag6.3USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5723606 No1999-12-152019-12-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityVery slightly soluble (0.15 mg/mL at 23 °C)Not Available
logP6.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00175 mg/mLALOGPS
logP5.23ALOGPS
logP5.44ChemAxon
logS-5.5ALOGPS
pKa (Strongest Acidic)11.14ChemAxon
pKa (Strongest Basic)6.23ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.09 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity150.83 m3·mol-1ChemAxon
Polarizability55.51 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  2. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  3. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
External Links
ATC CodesC03XA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (145 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Conivaptan can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.
2-mercaptobenzothiazoleThe metabolism of Conivaptan can be decreased when combined with 2-mercaptobenzothiazole.
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Conivaptan.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Conivaptan.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Conivaptan.
AdinazolamThe serum concentration of Adinazolam can be increased when it is combined with Conivaptan.
AlbendazoleThe serum concentration of Albendazole can be increased when it is combined with Conivaptan.
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Conivaptan.
AlfentanilThe serum concentration of Alfentanil can be increased when it is combined with Conivaptan.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Conivaptan.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Conivaptan.
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Conivaptan.
AllylestrenolThe serum concentration of Allylestrenol can be increased when it is combined with Conivaptan.
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Conivaptan.
AlogliptinThe serum concentration of Alogliptin can be increased when it is combined with Conivaptan.
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Conivaptan.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Conivaptan.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Conivaptan.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Conivaptan.
AmbroxolThe serum concentration of Ambroxol can be increased when it is combined with Conivaptan.
AminophenazoneThe serum concentration of Aminophenazone can be increased when it is combined with Conivaptan.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Conivaptan.
AmiodaroneThe serum concentration of Amiodarone can be increased when it is combined with Conivaptan.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Conivaptan.
AmlodipineThe serum concentration of Amlodipine can be increased when it is combined with Conivaptan.
AmorolfineThe metabolism of Conivaptan can be decreased when combined with Amorolfine.
Amphotericin BThe metabolism of Conivaptan can be decreased when combined with Amphotericin B.
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Conivaptan.
AN2690The metabolism of Conivaptan can be decreased when combined with AN2690.
AnidulafunginThe metabolism of Conivaptan can be decreased when combined with Anidulafungin.
AntipyrineThe serum concentration of Antipyrine can be increased when it is combined with Conivaptan.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Conivaptan.
ApremilastThe serum concentration of Apremilast can be increased when it is combined with Conivaptan.
AprepitantThe serum concentration of Conivaptan can be increased when it is combined with Aprepitant.
ArgatrobanThe serum concentration of Argatroban can be increased when it is combined with Conivaptan.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.
ArtemetherThe serum concentration of Artemether can be increased when it is combined with Conivaptan.
ArtemetherThe metabolism of Conivaptan can be decreased when combined with Artemether.
AsenapineThe serum concentration of Asenapine can be increased when it is combined with Conivaptan.
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Conivaptan.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Conivaptan.
AtomoxetineThe metabolism of Conivaptan can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Conivaptan.
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Conivaptan.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Conivaptan.
AzelastineThe serum concentration of Azelastine can be increased when it is combined with Conivaptan.
AzithromycinThe serum concentration of Azithromycin can be increased when it is combined with Conivaptan.
Bafilomycin A1The metabolism of Conivaptan can be decreased when combined with Bafilomycin A1.
BanoxantroneThe serum concentration of Banoxantrone can be increased when it is combined with Conivaptan.
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Conivaptan.
Benzoic AcidThe metabolism of Conivaptan can be decreased when combined with Benzoic Acid.
BenzphetamineThe serum concentration of Benzphetamine can be increased when it is combined with Conivaptan.
Benzyl alcoholThe serum concentration of Benzyl alcohol can be increased when it is combined with Conivaptan.
BexaroteneThe serum concentration of Bexarotene can be increased when it is combined with Conivaptan.
BexaroteneThe serum concentration of Conivaptan can be decreased when it is combined with Bexarotene.
BezafibrateThe serum concentration of Bezafibrate can be increased when it is combined with Conivaptan.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Conivaptan.
BicalutamideThe serum concentration of Bicalutamide can be increased when it is combined with Conivaptan.
BifonazoleThe metabolism of Conivaptan can be decreased when combined with Bifonazole.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Conivaptan.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Conivaptan.
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Conivaptan.
BortezomibThe metabolism of Conivaptan can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Conivaptan.
BosentanThe serum concentration of Conivaptan can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Conivaptan.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Conivaptan.
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Conivaptan.
BromazepamThe serum concentration of Bromazepam can be increased when it is combined with Conivaptan.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Conivaptan.
BrompheniramineThe serum concentration of Brompheniramine can be increased when it is combined with Conivaptan.
BudesonideThe metabolism of Budesonide can be decreased when combined with Conivaptan.
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Conivaptan.
BuprenorphineThe serum concentration of Buprenorphine can be increased when it is combined with Conivaptan.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Conivaptan.
BupropionThe serum concentration of Bupropion can be increased when it is combined with Conivaptan.
BuspironeThe serum concentration of Buspirone can be increased when it is combined with Conivaptan.
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Conivaptan.
ButenafineThe metabolism of Conivaptan can be decreased when combined with Butenafine.
ButoconazoleThe metabolism of Conivaptan can be decreased when combined with Butoconazole.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Conivaptan.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Conivaptan.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Conivaptan.
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Conivaptan.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Conivaptan.
CalcitriolThe serum concentration of Calcitriol can be increased when it is combined with Conivaptan.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Conivaptan.
CandicidinThe metabolism of Conivaptan can be decreased when combined with Candicidin.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Conivaptan.
CarbamazepineThe metabolism of Conivaptan can be increased when combined with Carbamazepine.
CarbinoxamineThe serum concentration of Carbinoxamine can be increased when it is combined with Conivaptan.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Conivaptan.
CariprazineThe serum concentration of Cariprazine can be increased when it is combined with Conivaptan.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Conivaptan.
CaspofunginThe metabolism of Conivaptan can be decreased when combined with Caspofungin.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Conivaptan.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Conivaptan.
CephalexinThe serum concentration of Cephalexin can be increased when it is combined with Conivaptan.
CeritinibThe serum concentration of Conivaptan can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Conivaptan.
CeruleninThe metabolism of Conivaptan can be decreased when combined with Cerulenin.
CevimelineThe serum concentration of Cevimeline can be increased when it is combined with Conivaptan.
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be increased when it is combined with Conivaptan.
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be increased when it is combined with Conivaptan.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Conivaptan.
ChloroxineThe metabolism of Conivaptan can be decreased when combined with Chloroxine.
ChlorphenamineThe serum concentration of Chlorphenamine can be increased when it is combined with Conivaptan.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Conivaptan.
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be increased when it is combined with Conivaptan.
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Conivaptan.
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Conivaptan.
CiclopiroxThe metabolism of Conivaptan can be decreased when combined with Ciclopirox.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Conivaptan.
CinacalcetThe serum concentration of Cinacalcet can be increased when it is combined with Conivaptan.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Conivaptan.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Conivaptan.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Conivaptan.
ClemastineThe metabolism of Conivaptan can be decreased when combined with Clemastine.
ClindamycinThe serum concentration of Clindamycin can be increased when it is combined with Conivaptan.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Conivaptan.
ClofazimineThe serum concentration of Clofazimine can be increased when it is combined with Conivaptan.
ClofibrateThe serum concentration of Clofibrate can be increased when it is combined with Conivaptan.
clomethiazoleThe serum concentration of clomethiazole can be increased when it is combined with Conivaptan.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Conivaptan.
ClonazepamThe serum concentration of Clonazepam can be increased when it is combined with Conivaptan.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Conivaptan.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Conivaptan.
ClorazepateThe serum concentration of Clorazepate can be increased when it is combined with Conivaptan.
ClotiazepamThe serum concentration of Clotiazepam can be increased when it is combined with Conivaptan.
ClotrimazoleThe metabolism of Conivaptan can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Conivaptan.
CobicistatThe serum concentration of Conivaptan can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Conivaptan.
CocaineThe serum concentration of Cocaine can be increased when it is combined with Conivaptan.
CodeineThe serum concentration of Codeine can be increased when it is combined with Conivaptan.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Conivaptan.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Conivaptan.
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Conivaptan.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Conivaptan can be decreased when combined with Crizotinib.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Conivaptan.
CyclophosphamideThe serum concentration of Cyclophosphamide can be increased when it is combined with Conivaptan.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Conivaptan.
CyclosporineThe metabolism of Conivaptan can be decreased when combined with Cyclosporine.
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Conivaptan.
DabrafenibThe serum concentration of Conivaptan can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Conivaptan.
DantroleneThe serum concentration of Dantrolene can be increased when it is combined with Conivaptan.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Conivaptan.
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Conivaptan.
DapsoneThe serum concentration of Dapsone can be increased when it is combined with Conivaptan.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Conivaptan.
DarunavirThe serum concentration of Darunavir can be increased when it is combined with Conivaptan.
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Conivaptan.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Conivaptan.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Conivaptan.
Decanoic AcidThe metabolism of Conivaptan can be decreased when combined with Decanoic Acid.
DeferasiroxThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be increased when it is combined with Conivaptan.
DelavirdineThe serum concentration of Delavirdine can be increased when it is combined with Conivaptan.
DelavirdineThe metabolism of Conivaptan can be decreased when combined with Delavirdine.
DesvenlafaxineThe serum concentration of Desvenlafaxine can be increased when it is combined with Conivaptan.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Conivaptan.
DexamethasoneThe serum concentration of Conivaptan can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Dextromethorphan can be increased when it is combined with Conivaptan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Conivaptan.
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be increased when it is combined with Conivaptan.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Conivaptan.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Conivaptan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Conivaptan.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Conivaptan.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Conivaptan.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Conivaptan.
DihydrocodeineThe serum concentration of Dihydrocodeine can be increased when it is combined with Conivaptan.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Conivaptan.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Conivaptan.
DihydroergotamineThe metabolism of Conivaptan can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Conivaptan.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Conivaptan.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Conivaptan.
DiltiazemThe metabolism of Conivaptan can be decreased when combined with Diltiazem.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Conivaptan.
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Conivaptan.
DisulfiramThe serum concentration of Disulfiram can be increased when it is combined with Conivaptan.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Conivaptan.
DolasetronThe serum concentration of Dolasetron can be increased when it is combined with Conivaptan.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Conivaptan.
DonepezilThe serum concentration of Donepezil can be increased when it is combined with Conivaptan.
DorzolamideThe serum concentration of Dorzolamide can be increased when it is combined with Conivaptan.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Conivaptan.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Conivaptan.
DoxycyclineThe metabolism of Conivaptan can be decreased when combined with Doxycycline.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Conivaptan.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Conivaptan.
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Conivaptan.
DronedaroneThe metabolism of Conivaptan can be decreased when combined with Dronedarone.
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Conivaptan.
EconazoleThe metabolism of Conivaptan can be decreased when combined with Econazole.
EfavirenzThe serum concentration of Efavirenz can be increased when it is combined with Conivaptan.
EfavirenzThe serum concentration of Conivaptan can be decreased when it is combined with Efavirenz.
EfinaconazoleThe metabolism of Conivaptan can be decreased when combined with Efinaconazole.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Conivaptan.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Conivaptan.
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Conivaptan.
EnalaprilThe serum concentration of Enalapril can be increased when it is combined with Conivaptan.
EnzalutamideThe serum concentration of Enzalutamide can be increased when it is combined with Conivaptan.
EnzalutamideThe serum concentration of Conivaptan can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Conivaptan.
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Conivaptan.
ErgocalciferolThe serum concentration of Ergocalciferol can be increased when it is combined with Conivaptan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Conivaptan.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Conivaptan.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Conivaptan.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Conivaptan.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Conivaptan.
ErythromycinThe metabolism of Conivaptan can be decreased when combined with Erythromycin.
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Conivaptan.
Eslicarbazepine acetateThe serum concentration of Conivaptan can be decreased when it is combined with Eslicarbazepine acetate.
EsomeprazoleThe serum concentration of Esomeprazole can be increased when it is combined with Conivaptan.
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Conivaptan.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Conivaptan.
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be increased when it is combined with Conivaptan.
EstramustineThe serum concentration of Estramustine can be increased when it is combined with Conivaptan.
EstroneThe serum concentration of Estrone can be increased when it is combined with Conivaptan.
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Conivaptan.
EszopicloneThe serum concentration of Eszopiclone can be increased when it is combined with Conivaptan.
EthanolThe serum concentration of Ethanol can be increased when it is combined with Conivaptan.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Conivaptan.
EthosuximideThe serum concentration of Ethosuximide can be increased when it is combined with Conivaptan.
EthylmorphineThe serum concentration of Ethylmorphine can be increased when it is combined with Conivaptan.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Conivaptan.
EtonogestrelThe serum concentration of Etonogestrel can be increased when it is combined with Conivaptan.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Conivaptan.
EtoricoxibThe serum concentration of Etoricoxib can be increased when it is combined with Conivaptan.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Conivaptan.
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Conivaptan.
EtravirineThe serum concentration of Conivaptan can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Conivaptan.
ExemestaneThe serum concentration of Exemestane can be increased when it is combined with Conivaptan.
FamciclovirThe serum concentration of Famciclovir can be increased when it is combined with Conivaptan.
FelbamateThe serum concentration of Felbamate can be increased when it is combined with Conivaptan.
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Conivaptan.
FenofibrateThe serum concentration of Fenofibrate can be increased when it is combined with Conivaptan.
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Conivaptan.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Conivaptan.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Conivaptan.
FinasterideThe serum concentration of Finasteride can be increased when it is combined with Conivaptan.
FingolimodThe serum concentration of Fingolimod can be increased when it is combined with Conivaptan.
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Conivaptan.
FluconazoleThe metabolism of Conivaptan can be decreased when combined with Fluconazole.
FlucytosineThe metabolism of Conivaptan can be decreased when combined with Flucytosine.
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Conivaptan.
FlunitrazepamThe serum concentration of Flunitrazepam can be increased when it is combined with Conivaptan.
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Conivaptan.
FluoxetineThe serum concentration of Fluoxetine can be increased when it is combined with Conivaptan.
FlurazepamThe serum concentration of Flurazepam can be increased when it is combined with Conivaptan.
FlutamideThe serum concentration of Flutamide can be increased when it is combined with Conivaptan.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Conivaptan.
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be increased when it is combined with Conivaptan.
FluvastatinThe serum concentration of Fluvastatin can be increased when it is combined with Conivaptan.
FluvoxamineThe metabolism of Conivaptan can be decreased when combined with Fluvoxamine.
FosamprenavirThe serum concentration of Fosamprenavir can be increased when it is combined with Conivaptan.
FosamprenavirThe metabolism of Conivaptan can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Conivaptan can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Conivaptan can be increased when combined with Fosphenytoin.
FulvestrantThe serum concentration of Fulvestrant can be increased when it is combined with Conivaptan.
Fusidic AcidThe serum concentration of Conivaptan can be increased when it is combined with Fusidic Acid.
GalantamineThe serum concentration of Galantamine can be increased when it is combined with Conivaptan.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Conivaptan.
GemfibrozilThe serum concentration of Gemfibrozil can be increased when it is combined with Conivaptan.
GlipizideThe serum concentration of Glipizide can be increased when it is combined with Conivaptan.
GlyburideThe serum concentration of Glyburide can be increased when it is combined with Conivaptan.
GlyphosateThe metabolism of Conivaptan can be decreased when combined with Glyphosate.
GranisetronThe serum concentration of Granisetron can be increased when it is combined with Conivaptan.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Conivaptan.
GriseofulvinThe metabolism of Conivaptan can be decreased when combined with Griseofulvin.
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Conivaptan.
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Conivaptan.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.
HaloproginThe metabolism of Conivaptan can be decreased when combined with Haloprogin.
HalothaneThe serum concentration of Halothane can be increased when it is combined with Conivaptan.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Conivaptan.
HexetidineThe metabolism of Conivaptan can be decreased when combined with Hexetidine.
HexobarbitalThe serum concentration of Hexobarbital can be increased when it is combined with Conivaptan.
Histamine PhosphateThe serum concentration of Histamine Phosphate can be increased when it is combined with Conivaptan.
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Conivaptan.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Conivaptan.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Conivaptan.
HydromorphoneThe serum concentration of Hydromorphone can be increased when it is combined with Conivaptan.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Conivaptan.
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be increased when it is combined with Conivaptan.
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Conivaptan.
IdelalisibThe serum concentration of Conivaptan can be increased when it is combined with Idelalisib.
IfosfamideThe serum concentration of Ifosfamide can be increased when it is combined with Conivaptan.
IloperidoneThe serum concentration of Iloperidone can be increased when it is combined with Conivaptan.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Conivaptan.
ImatinibThe metabolism of Conivaptan can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Conivaptan.
ImiquimodThe serum concentration of Imiquimod can be increased when it is combined with Conivaptan.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Conivaptan.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Conivaptan.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Conivaptan.
Ipratropium bromideThe serum concentration of Ipratropium bromide can be increased when it is combined with Conivaptan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Conivaptan.
IsavuconazoniumThe serum concentration of Isavuconazonium can be increased when it is combined with Conivaptan.
IsavuconazoniumThe metabolism of Conivaptan can be decreased when combined with Isavuconazonium.
IsoconazoleThe metabolism of Conivaptan can be decreased when combined with Isoconazole.
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be increased when it is combined with Conivaptan.
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Conivaptan.
IsradipineThe serum concentration of Isradipine can be increased when it is combined with Conivaptan.
IsradipineThe metabolism of Conivaptan can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Itraconazole can be increased when it is combined with Conivaptan.
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Conivaptan.
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Conivaptan.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Conivaptan.
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Conivaptan.
IxazomibThe serum concentration of Ixazomib can be increased when it is combined with Conivaptan.
KetamineThe serum concentration of Ketamine can be increased when it is combined with Conivaptan.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Conivaptan.
KetobemidoneThe serum concentration of Ketobemidone can be increased when it is combined with Conivaptan.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Conivaptan.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Conivaptan.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Conivaptan.
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Conivaptan.
LaquinimodThe serum concentration of Laquinimod can be increased when it is combined with Conivaptan.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Conivaptan.
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Conivaptan.
LetrozoleThe serum concentration of Letrozole can be increased when it is combined with Conivaptan.
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Conivaptan.
LevocetirizineThe serum concentration of Levocetirizine can be increased when it is combined with Conivaptan.
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be increased when it is combined with Conivaptan.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Conivaptan.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Conivaptan.
LevonorgestrelThe serum concentration of Levonorgestrel can be increased when it is combined with Conivaptan.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Conivaptan.
LevothyroxineThe serum concentration of Levothyroxine can be increased when it is combined with Conivaptan.
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Conivaptan.
LisurideThe serum concentration of Lisuride can be increased when it is combined with Conivaptan.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Conivaptan.
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Conivaptan.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Conivaptan.
LopinavirThe serum concentration of Lopinavir can be increased when it is combined with Conivaptan.
LoratadineThe serum concentration of Loratadine can be increased when it is combined with Conivaptan.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Conivaptan.
LosartanThe serum concentration of Losartan can be increased when it is combined with Conivaptan.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Conivaptan.
LovastatinThe metabolism of Conivaptan can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Conivaptan can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Conivaptan.
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Conivaptan.
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Conivaptan.
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Conivaptan.
MebendazoleThe serum concentration of Mebendazole can be increased when it is combined with Conivaptan.
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Conivaptan.
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Conivaptan.
MeloxicamThe serum concentration of Meloxicam can be increased when it is combined with Conivaptan.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Conivaptan.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Conivaptan.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Conivaptan.
MethaqualoneThe serum concentration of Methaqualone can be increased when it is combined with Conivaptan.
MethoxsalenThe serum concentration of Methoxsalen can be increased when it is combined with Conivaptan.
MethoxyfluraneThe serum concentration of Methoxyflurane can be increased when it is combined with Conivaptan.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Conivaptan.
MethyltestosteroneThe serum concentration of Methyltestosterone can be increased when it is combined with Conivaptan.
MetronidazoleThe serum concentration of Metronidazole can be increased when it is combined with Conivaptan.
MevastatinThe metabolism of Conivaptan can be decreased when combined with Mevastatin.
MexiletineThe serum concentration of Mexiletine can be increased when it is combined with Conivaptan.
MianserinThe serum concentration of Mianserin can be increased when it is combined with Conivaptan.
MibefradilThe serum concentration of Mibefradil can be increased when it is combined with Conivaptan.
MicafunginThe metabolism of Conivaptan can be decreased when combined with Micafungin.
MiconazoleThe serum concentration of Miconazole can be increased when it is combined with Conivaptan.
MiconazoleThe metabolism of Conivaptan can be decreased when combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Conivaptan.
MifepristoneThe serum concentration of Mifepristone can be increased when it is combined with Conivaptan.
MifepristoneThe metabolism of Conivaptan can be decreased when combined with Mifepristone.
MiltefosineThe metabolism of Conivaptan can be decreased when combined with Miltefosine.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Conivaptan.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.
MitotaneThe serum concentration of Conivaptan can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Modafinil can be increased when it is combined with Conivaptan.
ModafinilThe serum concentration of Conivaptan can be decreased when it is combined with Modafinil.
MonensinThe metabolism of Conivaptan can be decreased when combined with Monensin.
MontelukastThe serum concentration of Montelukast can be increased when it is combined with Conivaptan.
MorphineThe serum concentration of Morphine can be increased when it is combined with Conivaptan.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Conivaptan.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Conivaptan.
MyxothiazolThe metabolism of Conivaptan can be decreased when combined with Myxothiazol.
NafcillinThe serum concentration of Conivaptan can be decreased when it is combined with Nafcillin.
NaftifineThe metabolism of Conivaptan can be decreased when combined with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Conivaptan.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Conivaptan.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Conivaptan.
NatamycinThe metabolism of Conivaptan can be decreased when combined with Natamycin.
NateglinideThe serum concentration of Nateglinide can be increased when it is combined with Conivaptan.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Conivaptan.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Conivaptan.
NetupitantThe serum concentration of Conivaptan can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Nevirapine can be increased when it is combined with Conivaptan.
NevirapineThe metabolism of Conivaptan can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Conivaptan.
NicotineThe serum concentration of Nicotine can be increased when it is combined with Conivaptan.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Conivaptan.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Conivaptan.
NilotinibThe metabolism of Conivaptan can be decreased when combined with Nilotinib.
NilvadipineThe serum concentration of Nilvadipine can be increased when it is combined with Conivaptan.
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Conivaptan.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Conivaptan.
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Conivaptan.
NitrazepamThe serum concentration of Nitrazepam can be increased when it is combined with Conivaptan.
NitrendipineThe serum concentration of Nitrendipine can be increased when it is combined with Conivaptan.
NitroxolineThe metabolism of Conivaptan can be decreased when combined with Nitroxoline.
NorethisteroneThe serum concentration of Norethisterone can be increased when it is combined with Conivaptan.
NorgestrelThe serum concentration of Norgestrel can be increased when it is combined with Conivaptan.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Conivaptan.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Conivaptan.
NystatinThe metabolism of Conivaptan can be decreased when combined with Nystatin.
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Conivaptan.
OlaparibThe metabolism of Conivaptan can be decreased when combined with Olaparib.
OlopatadineThe serum concentration of Olopatadine can be increased when it is combined with Conivaptan.
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Conivaptan.
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Conivaptan.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Conivaptan.
OrphenadrineThe serum concentration of Orphenadrine can be increased when it is combined with Conivaptan.
OsimertinibThe serum concentration of Conivaptan can be increased when it is combined with Osimertinib.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Conivaptan.
OxazepamThe serum concentration of Oxazepam can be increased when it is combined with Conivaptan.
OxiconazoleThe metabolism of Conivaptan can be decreased when combined with Oxiconazole.
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Conivaptan.
OxycodoneThe serum concentration of Oxycodone can be increased when it is combined with Conivaptan.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Conivaptan.
OxymorphoneThe serum concentration of Oxymorphone can be increased when it is combined with Conivaptan.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Conivaptan.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Conivaptan.
pafuramidineThe metabolism of Conivaptan can be decreased when combined with pafuramidine.
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Conivaptan.
PalonosetronThe serum concentration of Palonosetron can be increased when it is combined with Conivaptan.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Conivaptan.
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Conivaptan.
ParamethadioneThe serum concentration of Paramethadione can be increased when it is combined with Conivaptan.
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Conivaptan.
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Conivaptan.
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Conivaptan.
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Conivaptan.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Conivaptan.
PentamidineThe serum concentration of Pentamidine can be increased when it is combined with Conivaptan.
PentamidineThe metabolism of Conivaptan can be decreased when combined with Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Conivaptan.
PentobarbitalThe metabolism of Conivaptan can be increased when combined with Pentobarbital.
PerampanelThe serum concentration of Perampanel can be increased when it is combined with Conivaptan.
PergolideThe serum concentration of Pergolide can be increased when it is combined with Conivaptan.
PerhexilineThe serum concentration of Perhexiline can be increased when it is combined with Conivaptan.
PermethrinThe serum concentration of Permethrin can be increased when it is combined with Conivaptan.
PerphenazineThe serum concentration of Perphenazine can be increased when it is combined with Conivaptan.
PethidineThe serum concentration of Pethidine can be increased when it is combined with Conivaptan.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Conivaptan.
PhenacetinThe serum concentration of Phenacetin can be increased when it is combined with Conivaptan.
PhenobarbitalThe metabolism of Conivaptan can be increased when combined with Phenobarbital.
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be increased when it is combined with Conivaptan.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Conivaptan.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Conivaptan.
PhenytoinThe metabolism of Conivaptan can be increased when combined with Phenytoin.
PilocarpineThe serum concentration of Pilocarpine can be increased when it is combined with Conivaptan.
PimecrolimusThe serum concentration of Pimecrolimus can be increased when it is combined with Conivaptan.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Conivaptan.
PinacidilThe serum concentration of Pinacidil can be increased when it is combined with Conivaptan.
PioglitazoneThe serum concentration of Pioglitazone can be increased when it is combined with Conivaptan.
PipotiazineThe serum concentration of Pipotiazine can be increased when it is combined with Conivaptan.
PodofiloxThe serum concentration of Podofilox can be increased when it is combined with Conivaptan.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Conivaptan.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Conivaptan.
PosaconazoleThe serum concentration of Posaconazole can be increased when it is combined with Conivaptan.
PrasugrelThe serum concentration of Prasugrel can be increased when it is combined with Conivaptan.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Conivaptan.
PrazepamThe serum concentration of Prazepam can be increased when it is combined with Conivaptan.
PraziquantelThe serum concentration of Praziquantel can be increased when it is combined with Conivaptan.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Conivaptan.
PrimaquineThe serum concentration of Primaquine can be increased when it is combined with Conivaptan.
PrimidoneThe metabolism of Conivaptan can be increased when combined with Primidone.
ProchlorperazineThe serum concentration of Prochlorperazine can be increased when it is combined with Conivaptan.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Conivaptan.
ProguanilThe serum concentration of Proguanil can be increased when it is combined with Conivaptan.
PromazineThe serum concentration of Promazine can be increased when it is combined with Conivaptan.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Conivaptan.
PropofolThe serum concentration of Propofol can be increased when it is combined with Conivaptan.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Conivaptan.
PyrazinamideThe serum concentration of Pyrazinamide can be increased when it is combined with Conivaptan.
QuazepamThe serum concentration of Quazepam can be increased when it is combined with Conivaptan.
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Conivaptan.
QuinacrineThe serum concentration of Quinacrine can be increased when it is combined with Conivaptan.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Conivaptan.
QuinineThe serum concentration of Quinine can be increased when it is combined with Conivaptan.
RabeprazoleThe serum concentration of Rabeprazole can be increased when it is combined with Conivaptan.
RadicicolThe metabolism of Conivaptan can be decreased when combined with Radicicol.
RaloxifeneThe serum concentration of Raloxifene can be increased when it is combined with Conivaptan.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Conivaptan.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Conivaptan.
RanolazineThe metabolism of Conivaptan can be decreased when combined with Ranolazine.
ReboxetineThe serum concentration of Reboxetine can be increased when it is combined with Conivaptan.
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Conivaptan.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Conivaptan.
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Conivaptan.
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Conivaptan.
RifabutinThe metabolism of Conivaptan can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Conivaptan.
RifampicinThe metabolism of Conivaptan can be increased when combined with Rifampicin.
RifapentineThe metabolism of Conivaptan can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Conivaptan.
RimonabantThe serum concentration of Rimonabant can be increased when it is combined with Conivaptan.
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Conivaptan.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Conivaptan.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Conivaptan.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Conivaptan.
RofecoxibThe serum concentration of Rofecoxib can be increased when it is combined with Conivaptan.
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Conivaptan.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Conivaptan.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Conivaptan.
RopivacaineThe serum concentration of Ropivacaine can be increased when it is combined with Conivaptan.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Conivaptan.
RotigotineThe serum concentration of Rotigotine can be increased when it is combined with Conivaptan.
RoxithromycinThe serum concentration of Roxithromycin can be increased when it is combined with Conivaptan.
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Conivaptan.
Salicylhydroxamic AcidThe metabolism of Conivaptan can be decreased when combined with Salicylhydroxamic Acid.
Salicylic acidThe metabolism of Conivaptan can be decreased when combined with Salicylic acid.
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Conivaptan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Conivaptan.
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Conivaptan.
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Conivaptan.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Conivaptan.
SeratrodastThe serum concentration of Seratrodast can be increased when it is combined with Conivaptan.
SertaconazoleThe metabolism of Conivaptan can be decreased when combined with Sertaconazole.
SertindoleThe serum concentration of Sertindole can be increased when it is combined with Conivaptan.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Conivaptan.
SevofluraneThe serum concentration of Sevoflurane can be increased when it is combined with Conivaptan.
SibutramineThe serum concentration of Sibutramine can be increased when it is combined with Conivaptan.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Conivaptan.
SildenafilThe metabolism of Conivaptan can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Conivaptan.
SiltuximabThe serum concentration of Conivaptan can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Conivaptan.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Conivaptan.
SinefunginThe metabolism of Conivaptan can be decreased when combined with Sinefungin.
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Conivaptan.
SirolimusThe metabolism of Conivaptan can be decreased when combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Conivaptan.
SolifenacinThe serum concentration of Solifenacin can be increased when it is combined with Conivaptan.
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Conivaptan.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Conivaptan.
SpiramycinThe serum concentration of Spiramycin can be increased when it is combined with Conivaptan.
St. John's WortThe serum concentration of Conivaptan can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Conivaptan can be increased when it is combined with Stiripentol.
SufentanilThe serum concentration of Sufentanil can be increased when it is combined with Conivaptan.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Conivaptan.
SulconazoleThe metabolism of Conivaptan can be decreased when combined with Sulconazole.
SulfadiazineThe serum concentration of Sulfadiazine can be increased when it is combined with Conivaptan.
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be increased when it is combined with Conivaptan.
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be increased when it is combined with Conivaptan.
SulfisoxazoleThe metabolism of Conivaptan can be decreased when combined with Sulfisoxazole.
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Conivaptan.
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Conivaptan.
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Conivaptan.
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Conivaptan.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Conivaptan.
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Conivaptan.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Conivaptan.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Conivaptan.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Conivaptan.
TasosartanThe serum concentration of Tasosartan can be increased when it is combined with Conivaptan.
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be increased when it is combined with Conivaptan.
TavaboroleThe metabolism of Conivaptan can be decreased when combined with Tavaborole.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Conivaptan.
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Conivaptan.
TemazepamThe serum concentration of Temazepam can be increased when it is combined with Conivaptan.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Conivaptan.
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Conivaptan.
TerbinafineThe serum concentration of Terbinafine can be increased when it is combined with Conivaptan.
TerbinafineThe metabolism of Conivaptan can be decreased when combined with Terbinafine.
TerconazoleThe metabolism of Conivaptan can be decreased when combined with Terconazole.
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Conivaptan.
TesmilifeneThe serum concentration of Tesmilifene can be increased when it is combined with Conivaptan.
TestosteroneThe serum concentration of Testosterone can be increased when it is combined with Conivaptan.
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Conivaptan.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Conivaptan.
ThiotepaThe serum concentration of Thiotepa can be increased when it is combined with Conivaptan.
ThymolThe metabolism of Conivaptan can be decreased when combined with Thymol.
TiagabineThe serum concentration of Tiagabine can be increased when it is combined with Conivaptan.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Conivaptan.
TiclopidineThe serum concentration of Ticlopidine can be increased when it is combined with Conivaptan.
TiclopidineThe metabolism of Conivaptan can be decreased when combined with Ticlopidine.
TinidazoleThe serum concentration of Tinidazole can be increased when it is combined with Conivaptan.
TioconazoleThe metabolism of Conivaptan can be decreased when combined with Tioconazole.
TiotropiumThe serum concentration of Tiotropium can be increased when it is combined with Conivaptan.
TipranavirThe serum concentration of Tipranavir can be increased when it is combined with Conivaptan.
TocilizumabThe serum concentration of Conivaptan can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Conivaptan.
TolnaftateThe metabolism of Conivaptan can be decreased when combined with Tolnaftate.
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Conivaptan.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Conivaptan.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Conivaptan.
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Conivaptan.
TramadolThe serum concentration of Tramadol can be increased when it is combined with Conivaptan.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Conivaptan.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Conivaptan.
TrazodoneThe serum concentration of Trazodone can be increased when it is combined with Conivaptan.
TretinoinThe serum concentration of Tretinoin can be increased when it is combined with Conivaptan.
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Conivaptan.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Conivaptan.
TrimethadioneThe serum concentration of Trimethadione can be increased when it is combined with Conivaptan.
TrimethoprimThe serum concentration of Trimethoprim can be increased when it is combined with Conivaptan.
TrimetrexateThe metabolism of Conivaptan can be decreased when combined with Trimetrexate.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Conivaptan.
TroglitazoneThe serum concentration of Troglitazone can be increased when it is combined with Conivaptan.
TroleandomycinThe serum concentration of Troleandomycin can be increased when it is combined with Conivaptan.
UdenafilThe serum concentration of Udenafil can be increased when it is combined with Conivaptan.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Conivaptan.
ValdecoxibThe serum concentration of Valdecoxib can be increased when it is combined with Conivaptan.
VandetanibThe serum concentration of Vandetanib can be increased when it is combined with Conivaptan.
VanoxerineThe serum concentration of Vanoxerine can be increased when it is combined with Conivaptan.
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Conivaptan.
VemurafenibThe serum concentration of Vemurafenib can be increased when it is combined with Conivaptan.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Conivaptan.
VenlafaxineThe metabolism of Conivaptan can be decreased when combined with Venlafaxine.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Conivaptan.
VerapamilThe metabolism of Conivaptan can be decreased when combined with Verapamil.
VicrivirocThe serum concentration of Vicriviroc can be increased when it is combined with Conivaptan.
VilanterolThe serum concentration of Vilanterol can be increased when it is combined with Conivaptan.
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Conivaptan.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Conivaptan.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Conivaptan.
VindesineThe serum concentration of Vindesine can be increased when it is combined with Conivaptan.
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Conivaptan.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Conivaptan.
VoriconazoleThe serum concentration of Voriconazole can be increased when it is combined with Conivaptan.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Conivaptan.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Conivaptan.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Conivaptan.
ZafirlukastThe serum concentration of Zafirlukast can be increased when it is combined with Conivaptan.
ZalcitabineThe serum concentration of Zalcitabine can be increased when it is combined with Conivaptan.
ZaleplonThe serum concentration of Zaleplon can be increased when it is combined with Conivaptan.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Conivaptan.
ZileutonThe serum concentration of Zileuton can be increased when it is combined with Conivaptan.
ZiprasidoneThe serum concentration of Ziprasidone can be increased when it is combined with Conivaptan.
ZiprasidoneThe metabolism of Conivaptan can be decreased when combined with Ziprasidone.
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Conivaptan.
ZomepiracThe serum concentration of Zomepirac can be increased when it is combined with Conivaptan.
ZonisamideThe serum concentration of Zonisamide can be increased when it is combined with Conivaptan.
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Conivaptan.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Conivaptan.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate a phosphatidyl-inositol-calcium second messenger system. Has been involved in social behaviors, including affiliation and attachment.
Gene Name:
AVPR1A
Uniprot ID:
P37288
Molecular Weight:
46799.105 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  3. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666 ]
  4. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003 ]
  5. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  6. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696 ]
  7. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376 ]
  8. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
  9. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103 ]
  10. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Vasopressin receptor activity
Specific Function:
Receptor for arginine vasopressin. The activity of this receptor is mediated by G proteins which activate adenylate cyclase. Involved in renal water reabsorption.
Gene Name:
AVPR2
Uniprot ID:
P30518
Molecular Weight:
40278.57 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Wada K, Fujimori A, Matsukawa U, Arai Y, Sudoh K, Yatsu T, Sasamata M, Miyata K: Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507(1-3):145-51. Epub 2005 Jan 1. [PubMed:15659304 ]
  3. Palm C, Pistrosch F, Herbrig K, Gross P: Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006 Jul;119(7 Suppl 1):S87-92. [PubMed:16843091 ]
  4. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
  5. Wada K, Matsukawa U, Fujimori A, Arai Y, Sudoh K, Sasamata M, Miyata K: A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Biol Pharm Bull. 2007 Jan;30(1):91-5. [PubMed:17202666 ]
  6. Walter KA: Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95. [PubMed:17592003 ]
  7. Mao ZL, Stalker D, Keirns J: Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther. 2009 Jul;31(7):1542-50. doi: 10.1016/j.clinthera.2009.07.011. [PubMed:19695403 ]
  8. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab. 2006 Jun;91(6):2145-52. Epub 2006 Mar 7. [PubMed:16522696 ]
  9. Annane D, Decaux G, Smith N: Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci. 2009 Jan;337(1):28-36. doi: 10.1097/MAJ.0b013e31817b8148. [PubMed:19057376 ]
  10. Ghali JK, Farah JO, Daifallah S, Zabalawi HA, Zmily HD: Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther. 2009 Dec 29;3:253-68. [PubMed:20054444 ]
  11. Ali F, Guglin M, Vaitkevicius P, Ghali JK: Therapeutic potential of vasopressin receptor antagonists. Drugs. 2007;67(6):847-58. [PubMed:17428103 ]
  12. Hoque MZ, Arumugham P, Huda N, Verma N, Afiniwala M, Karia DH: Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother. 2009 Sep;10(13):2161-9. doi: 10.1517/14656560903173237. [PubMed:19663609 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Ali F, Raufi MA, Washington B, Ghali JK: Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected]. Cardiovasc Drug Rev. 2007 Fall;25(3):261-79. [PubMed:17919259 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13